Tag: Cedars-Sinai Medical Center

New Videos in Carcinoid Cancer Foundation 2012-2013 Series

Faces of Hope and Surgery and Treatment Options are the newest videos in the Carcinoid Cancer Foundation’s 2012-2013 series.  Awareness and education are the first critical components in the fight against carcinoid and NET (neuroendocrine …

NETumor Humor Benefit

“If you’re laughing about it, you’re talking about it.”  Comedic performances by Greg Fitzsimmons, Frangela, Adam Ray, Andie Bolt, Eliana Horeczko, Fortune Feimster and more will be featured during the NEtTumor Humor Benefit at the Westside…

Carcinoid Cancer Foundation Releases New Video Series Beginning with “The ABC’s of Carcinoid/NETs”

What is the most common kind of neuroendocrine tumor (NET)?  How do these tumors grow?  What is carcinoid syndrome?  What are the quality of life issues for patients?  In “The ABC’s of Carcinoid/NETs,” three of the world’s leading carcinoid and NET cancer…

Carcinoid and Pancreatic Neuroendocrine Tumor Cancer Survivors Share Their Journeys

The Carcinoid Cancer Foundation is pleased to announce the addition of several new Survivor Stories on its website, www.carcinoid.org.  These are stories of courageous carcinoid and pancreatic neuroendocrine tumor (NET) survivors who, in several…

Carcinoid Cancer Foundation’s May 2011 Symposium Now Online

The Carcinoid Cancer Foundation is pleased to share with you videos from its carcinoid/NET symposium, “Neuroendocrine Tumor Management:  The Era of Personalized Medicine,” held on May 1, 2011 at Mt. Sinai Medical Center in New York City.

Following …

Now Recruiting: Carcinoid Syndrome Patients to Participate in Clinical Trial

Ipsen is recruiting patients with a history of carcinoid syndrome to participate in a clinical study to evaluate the effect of Somatuline® Depot (Lanreotide Autogel),  a somatostatin analog (SSTa) similar to octreotide, on the control of symptoms …

Lexicon Pharmaceuticals, Inc. Clinical Trial Recruiting Carcinoid Syndrome Patients

Patients with carcinoid syndrome, whose symptoms are not managed by octreotide therapy, are being recruited for a Phase 2 clinical trial of Lexicon Pharmaceuticals’ LX1606 (a.k.a. LX1032).  The trial has been given Fast Track status in the U.S. and …